iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) Sets New 1-Year High – Should You Buy?

Posted by Joseph Casey on Nov 17th, 2025

Shares of iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Get Free Report) hit a new 52-week high during trading on Monday . The stock traded as high as $81.22 and last traded at $81.1550, with a volume of 15092 shares. The stock had previously closed at $80.28.

iShares U.S. Pharmaceuticals ETF Stock Up 1.9%

The business has a 50 day moving average of $74.01 and a 200 day moving average of $69.42. The company has a market capitalization of $658.33 million, a P/E ratio of 17.75 and a beta of 0.54.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in IHE. IFP Advisors Inc boosted its position in iShares U.S. Pharmaceuticals ETF by 231.2% in the 1st quarter. IFP Advisors Inc now owns 944 shares of the company’s stock valued at $67,000 after buying an additional 659 shares during the period. LPL Financial LLC lifted its position in shares of iShares U.S. Pharmaceuticals ETF by 47.6% during the first quarter. LPL Financial LLC now owns 119,866 shares of the company’s stock valued at $8,458,000 after buying an additional 38,678 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in shares of iShares U.S. Pharmaceuticals ETF by 20.3% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,281 shares of the company’s stock worth $90,000 after acquiring an additional 216 shares in the last quarter. Liberty Wealth Management LLC purchased a new stake in iShares U.S. Pharmaceuticals ETF during the first quarter valued at approximately $848,000. Finally, Cookson Peirce & Co. Inc. acquired a new stake in iShares U.S. Pharmaceuticals ETF in the first quarter valued at approximately $214,000.

About iShares U.S. Pharmaceuticals ETF

(Get Free Report)

iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.